Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - benazepril hydrochloride (unii: n1sn99t69t) (benazeprilat - unii:jrm708l703), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - benazepril hydrochloride 10 mg - benazepril hcl and hydrochlorothiazide is indicated for the treatment of hypertension. this fixed combination drug is not indicated for the initial therapy of hypertension (see dosage and administration). benazepril hcl and hydrochlorothiazide is contraindicated in patients who are anuric. benazepril hcl and hydrochlorothiazide is also contraindicated in patients who are hypersensitive to benazepril, to any other ace inhibitor, to hydrochlorothiazide, or to other sulfonamide-derived drugs. hypersensitivity reactions are more likely to occur in patients with a history of allergy or bronchial asthma. benazepril hcl and hydrochlorothiazide is also contraindicated in patients with a history of angioedema with or without previous ace inhibitor treatment. benazepril hcl and hydrochlorothiazide is contraindicated in combination with a neprilysin (e.g., sacubitril). do not administer benazepril hcl and hydrochlorothiazide within 36 hours of switching to or from sacubitril/valsartan a neprilysin inhibitor (see warning

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - ofloxacin (unii: a4p49jaz9h) (ofloxacin - unii:a4p49jaz9h) - ofloxacin otic solution 0.3% is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: otitis externa in adults and pediatric patients, 6 months and older, due to escherichia coli, pseudomonas aeruginosa and staphylococcus aureus. chronic suppurative otitis media in patients 12 years and older with perforated tympanic membranes due to proteus mirabilis, pseudomonas aeruginosa and staphylococcus aureus. acute otitis media in pediatric patients one year and older with tympanostomy tubes due to haemophilus influenzae, moraxella catarrhalis, pseudomonas aeruginosa staphylococcus aureus, and streptococcus pneumoniae . ofloxacin otic solution 0.3% is contraindicated in patients with a history of hypersensitivity to ofloxacin, to other quinolones, or to any of the components in this medication.

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - disulfiram (unii: tr3mlj1uai) (disulfiram - unii:tr3mlj1uai) - disulfiram 250 mg - disulfiram is an aid in the management of selected chronic alcohol patients who want to remain in a state of enforced sobriety so that supportive and psychotherapeutic treatment may be applied to best advantage. disulfiram is not a cure for alcoholism. when used alone, without proper motivation and supportive therapy, it is unlikely that it will have any substantive effect on the drinking pattern of the chronic alcoholic. patients who are receiving or have recently received metronidazole, paraldehyde, alcohol, or alcohol-containing preparations, e.g., cough syrups, tonics and the like, should not be given disulfiram. disulfiram is contraindicated in the presence of severe myocardial disease or coronary occlusion, psychoses, and hypersensitivity to disulfiram or to other thiuram derivatives used in pesticides and rubber vulcanization.

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - desoximetasone (unii: 4e07gxb7au) (desoximetasone - unii:4e07gxb7au) - desoximetasone gel usp, 0.05% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. desoximetasone gel usp, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - metaxalone (unii: 1nma9j598y) (metaxalone - unii:1nma9j598y) - metaxalone tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions. the mode of action of this drug has not been clearly identified, but may be related to its sedative properties. metaxalone does not directly relax tense skeletal muscles in man. known hypersensitivity to any components of this product. known tendency to drug induced, hemolytic, or other anemias. significantly impaired renal or hepatic function.

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - trientine hydrochloride (unii: hc3nx54582) (trientine - unii:sj76y07h5f) - trientine hydrochloride is indicated in the treatment of patients with wilson's disease who are intolerant of penicillamine. clinical experience with trientine hydrochloride is limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient's dose have not been well defined. trientine hydrochloride and penicillamine cannot be considered interchangeable. trientine hydrochloride should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects. unlike penicillamine, trientine hydrochloride is not recommended in cystinuria or rheumatoid arthritis. the absence of a sulfhydryl moiety renders it incapable of binding cystine and, therefore, it is of no use in cystinuria. in 15 patients with rheumatoid arthritis, trientine hydrochloride was reported not to be effective in improving any clinical or biochemical parameter after 12 weeks of treatment. trientine hydrochloride is not indicated f

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - methimazole (unii: 554z48xn5e) (methimazole - unii:554z48xn5e) - methimazole 5 mg - methimazole tablets are indicated: methimazole tablets are contraindicated in the presence of hypersensitivity to the drug or any of the other product components.

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - glycopyrrolate (unii: v92so9wp2i) (glycopyrronium - unii:a14fb57v1d) - glycopyrrolate 1 mg - for use as adjunctive therapy in the treatment of peptic ulcer. glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus; intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis. glycopyrrolate tablets are contraindicated in those patients with a hypersensitivity to glycopyrrolate.

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - desoximetasone (unii: 4e07gxb7au) (desoximetasone - unii:4e07gxb7au) - desoximetasone ointment, 0.25% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. desoximetasone ointment, 0.25% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - predialysis patients calcitriol oral solution is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (ccr 15 to 55 ml/min) not yet on dialysis. in children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. a serum ipth level of ≥ 100 pg/ml is strongly suggestive of secondary hyperparathyroidism. dialysis patients calcitriol oral solution is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. in these patients, calcitriol oral solution administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. hypoparathyroidism patients calcitriol oral solution is also indicated in the management of hypocalcemia and its clinical manif